In the trial that won Juvederm Voluma XC its FDA approval, 67.1 percent of treated people still showed at least a one-grade improvement in mid-face volume at 24 months: The FDA summary puts it this way: "The duration of effect was evaluated by responder rate at 6 months to be 86%, at 12 months to be 85%, and at 24 months to be 67%."
Here is what that sentence is measuring, because it is not "how long the filler was there".
A responder is someone rated at least one grade better than their own starting point on a five-point scale of mid-face volume deficit — a scale developed by the manufacturer and validated for these trials. It is a rater's judgement of appearance, not a measurement of how much gel is left. Someone can be a non-responder and still have filler in place; they simply are not a full grade better than they were.
And 24 months is the length of the study, not the lifespan of the product: The trial ended there. It cannot tell you what happens at 30 months, because nobody was looking.
The responder rates across the whole follow-up were:
Month 6 — 85.6 percent: (this was the primary endpoint, and the pre-set success threshold was at least 70 percent)
Month 9 — 86.6 percent
Month 12 — 85.2 percent
Month 18 — 71.5 percent
Month 24 — 67.1 percent
The shape matters more than any single figure: The result held remarkably flat through the first year, then declined across the second. By the final visit, about one in three treated people no longer met even a one-grade improvement.
That is a more useful thing to know than "up to 2 years", which flattens a curve into a promise.
The pivotal was multicentre, single-blind and randomised, with 235 people treated and 47 assigned to a no-treatment control group.
Two design features shape how far the result travels.
The control arm received no treatment: That is a legitimate way to show a product does something rather than nothing. It is not a way to show a product does more than a different filler. This trial says nothing about how Voluma XC compares with any other product, and comparing responder rates across two separate trials — different scales, different raters, different people — is not a valid comparison.
The trial was run and submitted by the manufacturer in support of its own approval, using the manufacturer's own validated rating scale. That is normal and expected for a device approval, and the summary is a public FDA document. It is still worth knowing whose data it is.
Fillers are approved area by area through the FDA's premarket approval route, and each area required its own evidence. Voluma XC sits under PMA P110033, originally approved 22 October 2013.
Cheeks — the original 2013 approval: "Deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face in adults over the age of 21." This is the indication the 24-month figures above belong to.
Chin — added 12 June 2020: The indication was expanded to include "augmentation of the chin region to improve the chin profile in adults over the age of 21."
Temples — added 6 October 2023: Expanded again to include "supraperiosteal injection to augment the temple region to improve moderate to severe temple hollowing in adults over the age of 21." The temple pivotal ran on its own figures: 80.4 percent of treated people were responders at month 3, against 13.5 percent of no-treatment controls, and 73.3 percent were still responding at 13 months. Those are temple numbers from a temple trial and they are not interchangeable with the cheek numbers above.
The temple indication also comes with a restriction that is easy to miss: the FDA required a device-specific training programme, approved in May 2024 and updated in May 2025. It is a real, documented limit on who is meant to be injecting Voluma XC into the temples.
Voluma XC contains 20 mg/mL of hyaluronic acid with 0.3 percent lidocaine, cross-linked with BDDE. Cannula delivery was approved in 2019, and a threaded-hub cannula in 2020.
No published study predicts how long Voluma XC will last in a specific person: The trial reports group responder rates, not individual durations, and it did not identify factors that made some people last longer than others.
Two honest observations sit around the edges of that gap.
First, "gone" and "not a responder" are different things. A small MRI series of 33 selected patients found hyaluronic acid filler still detectable years after injection. That study was retrospective and selected, so it cannot say how common that is, and detectable on a scan is not the same as visible in the mirror. But it undercuts the mental model of filler simply dissolving away on a schedule, and its authors raised the question of whether repeat treatments are topping up a residual base rather than replacing something gone.
Second, the responder scale is a judgement, and it can move without treatment. In the pivotal trial for Juvederm Volux XC, 39.1 percent of an untreated control group were rated as responders at month 6. That is a different product in a different area, but it shows how soft a one-grade rating on these scales can be.
Voluma XC is hyaluronic acid, so hyaluronidase breaks it down. That is both the way an unwanted result is undone and the emergency treatment if filler blocks a blood vessel.
The caveat specific to this family of Juvederm gels is the dose: Published task force guidance states that these more heavily cross-linked products need "hundreds of units of hyaluronidase" to dissolve 1 cc — considerably more than other fillers. It is a practical point worth raising with an injector before treatment, not after.
Three further caveats apply to hyaluronidase generally. In the US it is off-label for dissolving filler: the Hylenex label lists only fluid administration, drug dispersion and urography. Repeat dosing is normal. And it is not a reliable rescue for filler-related blindness — in a review of 511 published cases, no treatment was significantly associated with visual improvement.
Which specific Juvederm product are you using, and in which area?
Which duration figure applies to that product in that area?
How many syringes would a full correction take, and over how many visits?
What will this look like at 12 months, and at 18?
Do you stock hyaluronidase, and how much?
For temples specifically: have you completed the manufacturer's required training programme?
Go to an emergency department or call 911 if any of these happen during or after an injection. They can mean filler has entered a blood vessel, and time is measured in hours.
Any change in vision: Blurring, a dark patch, double vision or loss of sight in one eye
Sudden severe pain, or pain out of proportion to the injection
Skin turning white (blanching), then dusky, purple, grey or net-like and mottled
Weakness, drooping, slurred speech, confusion or any other stroke-like symptom
The temple is a recognised danger zone, with vessels that connect toward the orbit. Do not wait to see whether symptoms settle.
Swelling keeps growing after the first few days instead of settling
A lump appears and does not soften over a couple of weeks
Redness spreads outward from the injection site
Tenderness, firmness or swelling appears weeks or months later, which can be a delayed inflammatory reaction or an infection
The filler seems to have moved from where it was placed
One side looks noticeably different from the other once the initial swelling has gone